Hematologist
CION Cancer Clinics
Transplant or more chemotherapy: how the decision is made | CION Cancer Clinics
Whether you have a transplant or more chemotherapy depends on one comparison: how likely the blood cancer is to return with chemotherapy alone, against the risk a transplant adds. High-risk genetic changes, leftover disease and a relapse lean towards a transplant. Lower-risk disease in deep remission, or poor fitness, lean towards chemotherapy. This page explains what is weighed, how the decision is made and what to ask. At CION Cancer Clinics, our haematology team assesses whether a transplant or CAR-T fits your situation and coordinates care with qualified centres.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- How do doctors decide between a transplant and more chemotherapy?
- What information goes into the decision?
- When does the balance usually favour each option?
- How is the decision actually made, step by step?
- What do families often assume about this choice?
- Are there options other than a transplant or more chemotherapy?
- What can this page not tell you?
- Common questions about transplant or chemotherapy
The short answer
How do doctors decide between a transplant and more chemotherapy?
The decision comes down to one comparison. How likely is the blood cancer to come back with chemotherapy alone, and how much risk does a transplant add to lower that chance? When the risk of relapse is high and you are fit enough, a transplant is usually advised. When it is low, more chemotherapy or other treatment is often the wiser path.
Why a transplant is not simply the stronger option
A donor transplant does two jobs. The high-dose treatment destroys the cancer cells, and the donor's immune cells go on hunting any that remain. That second effect is powerful. It also brings serious risks, including infections and graft-versus-host disease, where the donor cells attack your own body. Some people are harmed by the treatment itself.
Why chemotherapy alone is often enough
For many lower-risk blood cancers, chemotherapy, with or without targeted medicines, controls the disease well. In those cases a transplant adds danger without adding enough benefit. Choosing chemotherapy is then a sound medical decision, not a lesser one.
The ingredients
What information goes into the decision?
Your haematologist weighs these together. Ask which one is carrying the most weight in your case.
The genetic risk of the cancer
Tests on the cancer cells look for changes in the chromosomes and genes. Some changes carry a high chance of relapse; others a low one. This is often the single biggest factor.
Tests you may see named
- Cytogenetics or karyotype
- FISH
- Gene mutation panel
How the cancer responded
Whether the first treatment brought remission, meaning no cancer seen on tests, and how quickly. Leftover disease on a sensitive MRD test, measurable residual disease, often pushes towards a transplant.
Your fitness
Heart, lung, liver and kidney health, other illnesses and daily activity. A higher treatment risk narrows the benefit a transplant can offer.
Donor and timing
Whether a suitable donor exists and how quickly they can be ready. A long search can mean treating with chemotherapy in the meantime.
What matters to you
Time in hospital, distance from home, family support and how you feel about the risks. These are a legitimate part of the decision.
Not sure whether this applies to you?
Ask an oncologistWhich way it usually tips
When does the balance usually favour each option?
Leans towards chemotherapy alone
Leans towards a transplant
Favourable genetic changes in the cancer cells
High-risk genetic changes
Deep remission after the first treatment, with no residual disease found
Residual disease still found, or slow response
First remission in a lower-risk disease
Disease that has come back after treatment
Serious other illnesses or frailty
Good fitness and few other illnesses
No suitable donor available in time
A suitable donor ready
The process
How is the decision actually made, step by step?
-
Tests at diagnosis
The marrow sample is tested for genetic changes. Some results take a while to come back, so the first plan may be updated later.
-
First treatment
Almost everyone starts with chemotherapy or targeted treatment, whatever the later plan. A transplant is not usually the first step.
-
Checking the response
A repeat marrow test shows whether remission has been reached and whether residual disease remains.
-
Donor search, if needed
For higher-risk disease, family members are often tissue-typed early, so time is not lost if a transplant is advised.
-
Team discussion
Your case is discussed by several specialists together at a tumour board, not decided by one doctor alone.
-
Family meeting
The options, the reasons and the risks are explained. You can ask for time, a second opinion or a written summary before you decide.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What do families often assume about this choice?
"A transplant is always better if you can afford it."
Money does not change the medical balance. For lower-risk disease, a transplant can do more harm than good. The right choice depends on the cancer and the person, not the budget.
"If chemotherapy is chosen, the doctors think the case is hopeless."
Often it is the opposite. Chemotherapy alone is usually chosen because the disease is expected to respond well without the risks of a transplant.
"Once chemotherapy is chosen, a transplant is off the table."
Plans are reviewed as results come in. If the disease returns or tests show residual disease, a transplant may be discussed again, provided you remain fit enough.
"We should wait and see before deciding on a transplant."
For high-risk disease, the transplant usually works best while the cancer is in remission. Waiting for a relapse can close that window. Ask your team how much time you really have to decide.
Beyond the two choices
Are there options other than a transplant or more chemotherapy?
Yes. The choice is not always one or the other. Newer treatments sit alongside both, and some can bridge the gap until a transplant is possible.
Targeted medicines and immunotherapy
Some blood cancers carry changes that a targeted medicine can act on. Others respond to immunotherapy, including antibody treatments that help the immune system find the cancer. CAR-T cell therapy, where your own immune cells are changed to attack the cancer, is used for some relapsed leukaemias, lymphomas and myeloma. Access and eligibility vary, so ask whether any of these apply to you.
Who a transplant usually does not suit
A transplant is usually not advised when the cancer is not responding to any treatment, when serious heart, lung or liver disease makes the risk too high, or when lower-risk disease is well controlled without it. In those cases, other treatment and good symptom care give a better balance.
Being straight with you
What can this page not tell you?
This page cannot tell you which option is right for you. It cannot give an outlook for any one person either. The decision depends on test results only your haematologist has, and on a detailed talk about your own priorities.
Questions worth asking
What is the risk of relapse if we do not go ahead with a transplant? What is the risk from the transplant itself at the centre you recommend? Which test result is driving your advice? What happens if we wait? Ask for the answers in plain words, and ask again if they are not clear.
How CION can help
CION's haematology team reviews your reports, presents the case at a tumour board and helps coordinate care with qualified transplant centres.
Scheme and insurance cover, including Aarogyasri, PM-JAY, CGHS, ECHS, EHS and cashless policies, can differ between the two paths. Check the current rules for each before you decide.Questions we are asked
Common questions about transplant or chemotherapy
Who makes the final decision, the doctor or the family?
The medical team makes a recommendation based on the tests and the risks. The patient, with the family, decides whether to accept it. A good team explains the reasons clearly and respects a considered choice either way. You can ask for time to think before agreeing.
Why did the plan change after the genetic results came back?
Genetic tests on the cancer cells often take longer than the first blood results. They can move a leukaemia from a lower-risk to a higher-risk group, or the other way. A changed plan usually means the team is using better information, not that an earlier mistake was made.
What is MRD, and why does it matter so much?
MRD means measurable residual disease: tiny amounts of cancer that normal tests cannot see. A sensitive lab test looks for it. Finding MRD after treatment often signals a higher chance of relapse, which can make a transplant more strongly advised. Clearing it is a good sign.
Is an own-cell transplant the same kind of choice?
Not quite. An own-cell transplant, used mainly for myeloma and some lymphomas, is a way of giving very high-dose chemotherapy safely. It has no donor immune effect. The trade-off is different, and it is usually weighed against continuing medicines instead.
Can we change our mind after saying yes to a transplant?
Yes, before the conditioning treatment starts. Once the high-dose treatment begins, stopping is not safe because the marrow has been cleared. Raise any doubts early, and talk them through with the team rather than stepping away quietly.
Does choosing chemotherapy mean shorter treatment?
Not always. Some chemotherapy plans run for many months, with a long phase of tablets afterwards for certain leukaemias. A transplant involves a hospital stay and a long recovery. Ask for a realistic timeline for both options before deciding.
Should we get a second opinion before deciding?
It is reasonable, especially for a decision this important. Take every report, including the genetic and MRD results. Ask how quickly a decision is needed, so that a second opinion does not delay treatment for a disease where timing matters.
Can Dr. Basudev Pokhrel review our reports?
Dr. Basudev Pokhrel is CION's haematologist. The haematology team can look at your reports, explain the options in plain language and present the case at a tumour board. CION helps coordinate care with qualified transplant centres where a transplant is being considered.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Patient stories
Hear it from people we have treated
Every story is a video, in the patient's own words. Nothing here is a written testimonial.
Accreditation and empanelment
- NABH
- NABL
- ISO 9001:2015
- ArogyaSri empanelled
- CGHS accepted
- ECHS accepted
- EHS accepted
- Major cashless insurers
Paying for it
Insurance, schemes and payment
What you actually pay usually differs a great deal from the sticker figure.
AarogyasriEmpanelled. Bring the card and a referral where you have one.
CGHS / ECHS / EHSAccepted at CION centres for eligible treatment.
Cashless insuranceMost major insurers are empanelled. Pre-authorisation is handled by our desk.
Self-payItemised estimate given before treatment starts. No EMI scheme exists.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. A haematology consultation can be booked at any of these centres through one helpline, and your team will tell you where each test or treatment takes place.
Warangal
Vizag
Sources
- National Cancer Institute — Stem Cell Transplants in Cancer Treatment
- Cancer Research UK — Stem cell and bone marrow transplants
- American Cancer Society — Stem Cell Transplant for Cancer
- Leukemia & Lymphoma Society — Stem Cell Transplantation
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Talk to us
Facing the transplant question?
Share the reports. CION's haematology team will review them, discuss the case at a tumour board and help you reach a qualified transplant centre.